Compare QLYS & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QLYS | ERAS |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.3B |
| IPO Year | 2012 | 2021 |
| Metric | QLYS | ERAS |
|---|---|---|
| Price | $190.12 | $14.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 22 | 9 |
| Target Price | ★ $181.03 | $24.11 |
| AVG Volume (30 Days) | 600.4K | ★ 4.9M |
| Earning Date | 11-03-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 16.99 | ★ 36.23 |
| EPS | ★ 2.91 | N/A |
| Revenue | ★ $321,607,000.00 | N/A |
| Revenue This Year | $9.85 | N/A |
| Revenue Next Year | $8.22 | N/A |
| P/E Ratio | $65.01 | ★ N/A |
| Revenue Growth | ★ 15.32 | N/A |
| 52 Week Low | $74.51 | $2.11 |
| 52 Week High | $206.25 | $24.28 |
| Indicator | QLYS | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 53.37 | 45.11 |
| Support Level | $128.98 | $13.56 |
| Resistance Level | $191.57 | $15.03 |
| Average True Range (ATR) | 8.40 | 0.85 |
| MACD | -0.22 | 0.13 |
| Stochastic Oscillator | 59.65 | 41.32 |
Qualys is a cloud security and compliance solutions provider that helps businesses identify and manage their security risks and compliance requirements. The California-based company has more than 10,000 customers worldwide, the majority of which are small- and medium-size businesses. Qualys was founded in 1999 and went public in 2012.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.